Indivior Pharmaceuticals, Inc. (INDV): restructuring charge — Indivior announces restructuring charges of $39-$50 million as part of Indivior Action Agenda

Indivior Pharmaceuticals, Inc.

Headcount reductions expected to incur pre-tax severance charges of approximately $16 to $19 million in Q3 2025.
Real estate consolidation and exit costs estimated at $15 to $22 million pre-tax, including leasehold improvements and asset write-downs.
Consulting, legal, and tax planning expenses of about $8 to $9 million pre-tax, recognized in Q3 2025.
Company is exploring strategic alternatives for OPVEE and its non-U.S. business, which could result in further one-time costs.
Restructuring charges will be excluded from non-GAAP financial measures, consistent with reporting practices.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $39 to $50 million of restructuring charges pre-tax, of which $27-$35 million will be cash affecting enterprise-wide (pre-tax employee severance and related employee exit charges of approximately $16 to $19 million).

Type: restructuring
Charge: approximately $39 to $50 million of restructuring charges pre-tax, of which $27-$35 million will be cash
Affected area: enterprise-wide
Headcount: pre-tax employee severance and related employee exit charges of approximately $16 to $19 million

Exact text from the filing

which will be recognized in the third quarter of 2025. As a result of this initial initiative related to Phase 1, the Company expects to recognize a total of approximately $39 to $50 million of restructuring charges pre-tax, of which $27-$35 million will be cash, and which are expected to be recognized in the third and fourth quarters of 2025. These

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Indivior Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001625297-25-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.